Breaking News
Get 40% Off 0
☕ Buy the dip? After losing 17%, Starbucks sees an estimated 20% upside. See the top Undervalued stocks! Unlock list
Close

Beximco Pharmaceuticals Ltd. (BXPq)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
37.50 +1.00    +2.74%
03/05 - Closed. Currency in GBP ( Disclaimer )
  • Volume: 1,080
  • Bid/Ask: 34.00 / 39.00
  • Day's Range: 37.50 - 38.00
Type:  Equity
Market:  United Kingdom
ISIN:  US0885792061 
SEDOL:  B0DM5S5
Beximco Pharma. 37.50 +1.00 +2.74%

BXPq Income Statement & Profits

 
Assess the Beximco Pharmaceuticals Ltd. income statement, view the company's financial performance across their assets and liabilities. Select to view either quarterly or annual data.
AnnualQuarterly
Advanced Income Statement
Period Ending: 2024
31/03
2023
31/12
2023
30/09
2023
30/06
Total Revenue 10987.34 10904.21 11159.37 10033.69
Revenue 10987.34 10904.21 11159.37 10033.69
Other Revenue, Total - - - -
Cost of Revenue, Total 6184.08 6012.52 6277.73 5922.27
Gross Profit 4803.25 4891.69 4881.63 4111.42
Total Operating Expenses 9097.38 8767.72 8953.54 8498.96
Selling/General/Admin. Expenses, Total 2913.29 2755.21 2675.81 2576.69
Research & Development - - - 363.02
Depreciation / Amortization 433.45 429 431.21 -1352.49
Interest Expense (Income) - Net Operating -289.03 -273.95 -297.75 -276.4
Unusual Expense (Income) - - - -
Other Operating Expenses, Total -144.42 -155.06 -133.46 1265.87
Operating Income 1889.96 2136.49 2205.82 1534.73
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets - - 2.17 0.843
Other, Net 174.15 287.38 150.7 229.52
Net Income Before Taxes 1715.8 1849.11 2052.95 1304.37
Provision for Income Taxes 349.25 408.34 485.54 345.71
Net Income After Taxes 1366.56 1440.77 1567.4 958.66
Minority Interest 3939.52 3937.48 3953.45 3938.96
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 1364.52 1433.47 1552.91 979.47
Total Extraordinary Items - - - -
Net Income 1364.52 1433.47 1552.91 979.47
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items 1364.52 1433.47 1552.91 979.47
Dilution Adjustment - - - -
Diluted Net Income 1364.52 1433.47 1552.91 979.47
Diluted Weighted Average Shares 446.11 446.11 446.11 446.11
Diluted EPS Excluding Extraordinary Items 3.06 3.21 3.48 2.2
DPS - Common Stock Primary Issue - - - 3.5
Diluted Normalized EPS 2.4 2.57 2.84 1.86
* In Millions of BDT (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BXPq Price Commentary

Write your thoughts about Beximco Pharmaceuticals Ltd.
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Quazi Hossain Tito
Quazi Hossain Tito Nov 21, 2022 9:28
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it's a good share in our BD market. don't understand why UK investors are taking the share so low!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email